Gynae BT 2017

EBRT for gyn cancer treatment

• Elective dose including draining lymphatic system

• Boost to regional pathologic nodes

• Boost to primary tumor if brachytherapy is not feasible

• Dose needed for tumor control to high for surrounding OAR

• Reduction according to ALARA, as low as reasonably achievable

• Dose constraints and DVH parameters help to balance between tumor dose and OAR dose